Vmn1r61 inhibitors refer to a class of compounds that are designed to interact with the Vmn1r61 receptor, a specific member of the vomeronasal 1 receptor family. The Vmn1r family is part of the larger class of G-protein-coupled receptors (GPCRs) and is primarily involved in chemosensory signaling. These receptors are expressed in the vomeronasal organ (VNO), an olfactory structure that plays a significant role in detecting pheromones and other chemical stimuli, particularly in certain vertebrates. The Vmn1r61 receptor, specifically, is believed to mediate the detection of specific chemical ligands, which can result in various downstream signaling cascades within cells. Inhibitors of Vmn1r61 work by binding to the receptor or interfering with its natural ligands, thereby blocking its normal function.
The design and study of Vmn1r61 inhibitors involves understanding the receptor's structure, its binding pocket, and the chemical interactions that drive ligand binding. These inhibitors are often synthesized and characterized based on their ability to modulate receptor-ligand interactions. This process typically involves structural analysis techniques such as computational modeling, molecular docking, and biochemical assays to determine how these compounds affect receptor activity. These inhibitors are essential tools for studying the underlying mechanisms of chemosensory systems, offering insights into the molecular basis of receptor function and the signaling pathways that follow activation or inhibition. By inhibiting Vmn1r61, researchers can dissect the receptor's role in various biological processes without reference to broader applications or implications.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist that can modulate GPCR signaling, potentially affecting Vmn1r61 indirectly. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, may alter GPCR-mediated processes potentially impacting Vmn1r61. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, might affect GPCR signaling pathways, influencing Vmn1r61 indirectly. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect noradrenergic signaling, possibly related to Vmn1r61. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, might modulate GPCR pathways potentially influencing Vmn1r61 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, could affect calcium signaling pathways, potentially related to Vmn1r61. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, could affect GPCR-mediated signaling pathways involved with Vmn1r61. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r61. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r61 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r61. | ||||||